Eli Lilly and Company (LLY)

Eli Lilly's stock experienced several notable events over the past six months. In October 2025, the stock rose by 10% due to strong clinical trial progress for orforglipron and the acquisition of Adverum Biotechnologies. Also in October 2025, Omvoh (Mirikizumab-MRKZ) demonstrated a 55% reduction in bowel urgency episodes by week 12 for patients with ulcerative colitis. Jefferies initiated coverage of Eli Lilly, highlighting increasing competition in the GLP-1 market. In September 2025, the stock price fell modestly after Phase 3 data for orforglipron in obesity fell short of investor expectations. In August 2025, Eli Lilly reported strong quarterly earnings, exceeding consensus estimates. In August 2024, Eli Lilly announced the direct-to-consumer availability of Zepbound. In January 2025, Eli Lilly revised its revenue outlook for the fourth quarter of 2024, lowering it by $400 million due to weaker-than-expected demand for its weight-loss drugs, Zepbound and Mounjaro, leading to a 6% drop in shares.

There is a consistent and rapidly increasing demand for Eli Lilly's GLP-1 therapies, Mounjaro and Zepbound, for diabetes and weight loss. Despite a temporary adjustment in Q4 2024 revenue guidance due to lower channel inventory, the underlying demand for these drugs remained strong. The company's diversified business mix suggests a less pronounced overall seasonality.

Eli Lilly & Co. is a multinational pharmaceutical company focused on discovering, developing, manufacturing, and selling pharmaceutical products. Its portfolio includes treatments for diabetes, oncology, immunology, neuroscience, and other therapeutic areas. Key products include tirzepatide (Mounjaro/Zepbound), abemaciclib (Verzenio), dulaglutide (Trulicity), Humalog, Jardiance, and Taltz. Mounjaro and Zepbound accounted for 37% of the company's 2024 revenues, while Verzenio contributed 12%. The company's pipeline includes Donanemab, an Alzheimer's disease drug that received FDA approval in 2025.

Eli Lilly and Company has a substantial international presence, with offices in 18 countries and its products sold in approximately 125 countries. Around one-third of its revenues are generated outside the United States. The company expanded overseas in the 1930s, establishing its first overseas subsidiary in London in 1934 and opening a manufacturing plant in Basingstoke. Eli Lilly has also announced plans to invest billions in manufacturing facilities in Texas and Virginia, and has made a $1.8 billion manufacturing investment in Ireland and a $4.5 billion investment in the Lilly Medicine Foundry in Indiana. A new $2.5 billion site in Germany is also aimed at ramping up production.

Eli Lilly's brand reputation has been shaped by its advancements in diabetes and obesity treatments, particularly Mounjaro and Zepbound. The company's commitment to expanding manufacturing capacity and the FDA approval of Donanemab have enhanced its reputation. However, a slight miss in investor expectations for orforglipron and a revised revenue outlook caused minor stock price dips. The company's move to a direct-to-consumer model for Zepbound represents an innovative approach to patient access and affordability.

Lilly Endowment Inc. holds 10.8% of Eli Lilly and Company. Institutional investors and hedge funds actively trade shares of Eli Lilly. Sapient Capital increased its position in Eli Lilly by 259,392 shares in Q3 2025, while Generali Asset Management reduced its stake by selling 6,430 shares in October 2025. Insiders have also been active, with Director Gabrielle Sulzberger purchasing 117 shares and Director J Erik Fyrwald acquiring 1,565 shares in August 2025.